| Literature DB >> 31487687 |
Al B Benson1, Alan P Venook2, Mahmoud M Al-Hawary3, Mustafa A Arain2, Yi-Jen Chen4, Kristen K Ciombor5, Stacey A Cohen6, Harry S Cooper7, Dustin A Deming8, Ignacio Garrido-Laguna9, Jean L Grem10, Sarah E Hoffe11, Joleen Hubbard12, Steven Hunt13, Ahmed Kamel14, Natalie Kirilcuk15, Smitha Krishnamurthi16, Wells A Messersmith17, Jeffrey Meyerhardt18, Eric D Miller19, Mary F Mulcahy1, Steven Nurkin20, Michael J Overman21, Aparna Parikh22, Hitendra Patel23, Katrina S Pedersen13, Leonard B Saltz24, Charles Schneider25, David Shibata26, John M Skibber21, Constantinos T Sofocleous24, Elena M Stoffel3, Eden Stotsky-Himelfarb27, Christopher G Willett28, Alyse Johnson-Chilla29, Kristina M Gregory29, Lisa A Gurski29.
Abstract
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.Entities:
Mesh：
Year: 2019 PMID： 31487687 DOI： 10.6004/jnccn.2019.0043
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908